Jason T Huse, M.D., Ph.D.
Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div
About Dr. Jason T Huse
I am a Neuropathologist and Cancer Biologist who studies the molecular pathogenesis of primary brain tumors and brain metastases. My research group is focused on elucidating the epigenetic and transcriptional events underlying brain tumor initiation and maintenance. Over the past several years, we have characterized the genomic, epigenomic, and cellular consequences of ATRX deficiency in astrocytic gliomas. We have also identified metabolic and immunologic abnormalities that appear to promote brain metastasis across tumor type. Our work continues to demonstrate viable avenues for therapeutic development.
In addition to maintaining an active research lab, irregularly attend on the Neuropathology clinical service.
Present Title & Affiliation
Primary Appointment
Professor with Tenure, Department of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Education & Training
Degree-Granting Education
| 2003 | University of Pennsylvania School of Medicine, Philadelphia, PA, USA, MD, Neurology |
| 2002 | University of Pennsylvania School of Medicine, Philadelphia, PA, USA, PhD, Neuroscience |
| 1996 | Princeton University, Princeton, NJ, USA, BA, Chemistry |
Postgraduate Training
| 2006-2009 | Research Fellowship, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY |
| 2005-2007 | Clinical Fellowship, Neuropathology, Hospital of the University of Pennsylvania, Philadelphia, PA |
| 2003-2005 | Clinical Residency, Anatomic Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA |
Board Certifications
| 2007 | Anatomic Pathology |
| 2007 | Neuropathology |
Experience & Service
Academic Appointments
Associate Professor with Tenure, Department of Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2021
Assistant Member, Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, 2009 - 2016
Other Appointments/Responsibilities
Faculty Member, UT GSBS Cancer Biology Program, Houston, TX, 2016 - Present
Director, Brain Tumor Tissue Bank, University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present
Honors & Awards
| 2021 | Excellence in Research, MD Anderson Cancer Center |
| 2017 | American Cancer Society Research Scholar, American Cancer Society |
| 2012 | Sontag Foundation Distinguished Scientist Award, Sontag Foundation |
| 2012 | Doris Duke Clinical Scientist Development Award, Doris Duke Charitable Foundation |
| 2012 | Sidney Kimmel Translational Science Award, Sidney Kimmel Foundation |
| 2011 | Landon Innovator Award for Research in Personalized Cancer Medicine, American Association for Cancer Research |
| 2009 | Leon Levy Foundation Young Investigator, Leon Levy Foundation |
| 2009 | Weil Award for the Best Paper in Experimental Neuropathology, American Association of Neuropathologists |
| 2009 | Revson/Winston Fellow in Biomedical Research, Memorial Sloan-Kettering Cancer Center |
| 2006 | David Tetenbaum Hope/American Brain Tumor Association Fellow, American Brain Tumor Association |
| 2003 | Jesse H. Frank Prize in Pathology, University of Pennsylvania School of Medicine |
| 2002 | Louise B. Flexner Student Prize for Outstanding Dissertation, University of Pennsylvania Institute of Neuroscience |
| 2002 | Saul Wingrad Award for Outstanding Dissertation, University of Pennsylvania Department of Neuroscience |
| 2001 | Robert M. Toll Medical Student Research Prize, University of Pennsylvania School of Medicine |
| 1999 | Howard Hughes Medical Institute Predoctoral Fellow, Howard Hughes Medical Institute |
Selected Publications
Peer-Reviewed Articles
- Fukumura K, Malgulwar PB, Fischer GM, Hu X, Mao X, Song X, Hernandez SD, Zhang XH, Zhang J, Parra ER, Yu D, Debeb BG, Davies MA, Huse JT. Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol 141(2):303-321, 2021. e-Pub 2021. PMID: 33394124.
- Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
- Chang G, Shi L, Ye Y, Shi H, Zeng L, Tiwary S, Huse JT, Huo L, Ma L, Ma Y, Zhang S, Zhu J, Xie V, Li P, Han L, He C, Huang S. YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. Cancer Cell. e-Pub 2020. PMID: 33125861.
- Ott M, Tomaszowski KH, Marisetty A, Kong LY, Wei J, Duna M, Blumberg K, Ji X, Jacobs C, Fuller GN, Langford LA, Huse JT, Long JP, Hu J, Li S, Weinberg JS, Prabhu SS, Sawaya R, Ferguson S, Rao G, Lang FF, Curran MA, Heimberger AB. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight 5(17), 2020. e-Pub 2020. PMID: 32721947.
- Akkari L, Bowman RL, Tessier J, Klemm F, Handgraaf SM, de Groot M, Quail DF, Tillard L, Gadiot J, Huse JT, Brandsma D, Westerga J, Watts C, Joyce JA. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci Transl Med 12(552), 2020. PMID: 32669424.
- Zhang L, Yao J, Wei Y, Zhou Z, Li P, Qu J, Badu-Nkansah A, Yuan X, Huang YW, Fukumura K, Mao X, Chang WC, Saunus J, Lakhani S, Huse JT, Hung MC, Yu D. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Sci Transl Med 12(545), 2020. PMID: 32461334.
- de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. PMID: 31755915.
- Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses; results from a Phase I/II trial. Clin Cancer Res. e-Pub 2020. PMID: 32299815.
- Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Sci Adv 6(17):eaaz3221, 2020. e-Pub 2020. PMID: 32494639.
- Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, LaRocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Amos CI, Huse JT, Barnholtz-Sloan JS, Bondy ML. Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. Int J Cancer 146(3):739-748, 2020. e-Pub 2019. PMID: 30963577.
- Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW, GLASS Consortium. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 576(7785):112-120, 2019. e-Pub 2019. PMID: 31748746.
- Juthani R, Madajewski B, Yoo B, Zhang L, Chen PM, Chen F, Turker MZ, Ma K, Overholtzer M, Longo VA, Carlin S, Aragon-Sanabria V, Huse JT, Gonen M, Zanzonico PB, Rudin CM, Wiesner U, Bradbury MS, Brennan CW. Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clin Cancer Res. e-Pub 2019. PMID: 31515460.
- Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol 30(9):1521-1530, 2019. PMID: 31282941.
- Elshafeey N, Kotrotsou A, Hassan A, Elshafei N, Hassan I, Ahmed S, Abrol S, Agarwal A, El Salek K, Bergamaschi S, Acharya J, Moron FE, Law M, Fuller GN, Huse JT, Zinn PO, Colen RR. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun 10(1):3170, 2019. e-Pub 2019. PMID: 31320621.
- Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov 9(5):628-645, 2019. e-Pub 2019. PMID: 30787016.
- Farooqi A, Yang J, Sharin V, Ezhilarasan R, Danussi C, Alvarez C, Dharmaiah S, Irvin D, Huse J, Sulman EP. Identification of patient-derived glioblastoma stem cell (GSC) lines with the alternative lengthening of telomeres phenotype. Acta Neuropathol Commun 7(1):76, 2019. e-Pub 2019. PMID: 31097032.
- Ballester LY, Moghadamtousi SZ, Leeds NE, Huse JT, Fuller GN. Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases. Acta Neuropathol Commun 7(1):63, 2019. e-Pub 2019. PMID: 31036092.
- Mandel JJ, Youssef M, Nam J, Patel AJ, Jalali A, Ludmir EB, Liu D, Wu J, Armstrong G, Huse J, Bondy M, de Groot JF. Effect of health disparities on overall survival of patients with glioblastoma. J Neurooncol 142(2):365-374, 2019. e-Pub 2019. PMID: 30671709.
- Hovinga KE, McCrea HJ, Brennan C, Huse J, Zheng J, Esquenazi Y, Panageas KS, Tabar V. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. J Neurooncol 142(2):337-345, 2019. e-Pub 2019. PMID: 30680510.
- Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol 37(9):741-750, 2019. e-Pub 2019. PMID: 30715997.
- Wang Y, Yang J, Wild AT, Wu WH, Shah R, Danussi C, Riggins GJ, Kannan K, Sulman EP, Chan TA, Huse JT. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nat Commun 10(1):943, 2019. e-Pub 2019. PMID: 30808951.
- Gates EDH, Yang J, Fukumura K, Lin JS, Weinberg JS, Prabhu SS, Long L, Fuentes D, Sulman EP, Huse JT, Schellingerhout D. Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. Front Oncol 9:676, 2019. e-Pub 2019. PMID: 31417865.
- Kaffes I, Szulzewsky F, Chen Z, Herting CJ, Gabanic B, Velázquez Vega JE, Shelton J, Switchenko JM, Ross JL, McSwain LF, Huse JT, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L, Maturi NP, Cimino PJ, Holland EC, Kettenmann H, Brennan CW, Brat DJ, Hambardzumyan D. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncoimmunology 8(11):e1655360, 2019. e-Pub 2019. PMID: 31646100.
- Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong LY, Ling X, Caruso H, Zhou S, Wang YA, Fuller GN, Huse J, Gilboa E, Kang N, Huang X, Verhaak R, Li S, Heimberger AB. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest 129(1):137-149, 2019. e-Pub 2018. PMID: 30307407.
- Jacobs DI, Fukumura K, Bainbridge MN, Armstrong GN, Tsavachidis S, Gu X, Doddapaneni HV, Hu J, Jayaseelan JC, Muzny DM, Huse JT, Bondy ML. Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series. Neuro Oncol 20(12):1625-1633, 2018. PMID: 30165405.
- Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. J Neuropathol Exp Neurol 77(7):628-635, 2018. PMID: 29873738.
- Oldrini B, Curiel-García Á, Marques C, Matia V, Uluçkan Ö, Graña-Castro O, Torres-Ruiz R, Rodriguez-Perales S, Huse JT, Squatrito M. Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nat Commun 9(1):1466, 2018. e-Pub 2018. PMID: 29654229.
- Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nat Commun 9(1):1057, 2018. e-Pub 2018. PMID: 29535300.
- Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, Zheng Y, El-Amine N, Haddock S, Nanjangud G, LeKaye HC, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB, Chan TA. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat Genet 50(1):62-72, 2018. e-Pub 2017. PMID: 29180699.
- Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology 7(4):e1412909, 2018. e-Pub 2018. PMID: 29632728.
- Lee SH, Kim JS, Zheng S, Huse JT, Bae JS, Lee JW, Yoo KH, Koo HH, Kyung S, Park WY, Sung KW. ARID1B alterations identify aggressive tumors in neuroblastoma. Oncotarget 8(28):45943-45950, 2017. PMID: 28521285.
- Yan D, Kowal J, Akkari L, Schuhmacher AJ, Huse JT, West BL, Joyce JA. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene. e-Pub 2017. PMID: 28759044.
- Rajappa P, Cobb WS, Vartanian E, Huang Y, Daly L, Hoffman C, Zhang J, Shen B, Yanowitch R, Garg K, Cisse B, Haddock S, Huse J, Pisapia DJ, Chan TA, Lyden DC, Bromberg JF, Greenfield JP. Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. Clin Cancer Res 23(12):3109-3119, 2017. e-Pub 2016. PMID: 28039266.
- Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. Multicenter Phase II Study of Temozolomide and Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Newly Diagnosed Anaplastic Oligodendroglioma. Neuro Oncol. e-Pub 2017. PMID: 28472509.
- Huang Y, Rajappa P, Hu W, Hoffman C, Cisse B, Kim JH, Gorge E, Yanowitch R, Cope W, Vartanian E, Xu R, Zhang T, Pisapia D, Xiang J, Huse J, Matei I, Peinado H, Bromberg J, Holland E, Ding BS, Rafii S, Lyden D, Greenfield J. A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. J Clin Invest 127(5):1826-1838, 2017. e-Pub 2017. PMID: 28394259.
- Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper D, Karajannis MA, Benayed R, Chavez L, Thomas C, Serrano J, Borsu L, Ladanyi M, Rosenblum MK. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 133(3):417-429, 2017. e-Pub 2016. PMID: 27812792.
- Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. e-Pub 2017. PMID: 28371827.
- Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J, Bose P, Lee W, Chan TA. Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. Cancer Cell 29(5):737-50, 2016. PMID: 27165745.
- Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC, Joyce JA. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352(6288):aad3018, 2016. PMID: 27199435.
- Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol 18(4):557-64, 2016. e-Pub 2015. PMID: 26449250.
- Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, TCGA Research Network, Noushmehr H, Iavarone A, Verhaak RG. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164(3):550-63, 2016. PMID: 26824661.
Grant & Contract Support
| Title: | Characterizing the epigenetic consequences of ATRX deficiency in cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | Principal Investigator |
| Title: | Characterizing the Relationship between Germline and Somatic Alterations in Gliomagenesis and Clinical Outcomes |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Title: | SPORE in Brain Cancer (Core B) |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Credentialing murine models for glioblastoma preclinical drug development |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Characterizing Heterochromatin Dysfunction as a Driving Alteration in Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Title: | Discovery, biology and risk of inherited variants in glioma |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
Patient Reviews
CV information above last modified May 30, 2024